Investor Presentaiton
2023 GUIDANCE
Prior
Updated
REVENUE
$31.2 $31.7 billion
$33.4 $33.9 billion
GROSS MARGIN % OF REVENUE (GAAP)
GROSS MARGIN % OF REVENUE (NON-GAAP)
Approx. 77%
Approx. 79%
Approx. 78%
Approx. 80%
MKTG, SELLING & ADMIN.
$7.0 $7.2 billion
$7.2 $7.4 billion
RESEARCH & DEVELOPMENT
ACQUIRED IPR&D
OTHER INCOME/(EXPENSE) (GAAP)
OTHER INCOME/(EXPENSE) (NON-GAAP)
TAX RATE
EARNINGS PER SHARE (GAAP)
EARNINGS PER SHARE (NON-GAAP)
Assumes shares outstanding of 903 million
Not for promotional use
$8.3 $8.5 billion
$8.9 $9.1 billion
$105 million
$202 million
-
$(200) $(100) million
$(75) - $25 million
$0 $100 million
Approx. 13%
14% - 15%
$8.18
$8.38
$8.65 - $8.85
$9.20 - $9.40
$9.70 - $9.90
2023 Q2 EARNINGS
Lilly
COMMENTS
Increased range reflects revenue from the sales of rights for Baqsimi and
olanzapine as well as strong performance in underlying business
Increase driven by the sales of rights for Baqsimi and our olanzapine
portfolio
Increase reflects additional investments in recent launches and
preparation for launches expected later this year
Increase reflects additional investments in the late-stage portfolio and
early-stage research and expected incremental expense from business
development activities
Incorporated IPR&D charges that have been incurred through Q2 2023;
does not include any IPR&D charges associated with potential or pending
business development transactions
Increase driven by the interest impact of higher cash balances; reported
guidance incorporates net losses on investments in equity securities
Increase reflects the impact from the sales of rights for the olanzapine
portfolio and Baqsimi
FX assumptions: 1.12 (Euro), 139 (Yen) and 7.1 (Renminbi)
13View entire presentation